Tumor cells upregulate normoxic HIF-1a in response to doxorubicin

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6230-6242

  Cao, Yiting ^a   Eble, Joseph M ^c   Moon, Ejung ^a,d   Yuan, Hong ^b   Weitzel, Douglas H ^a   Landon, Chelsea D ^a   Nien, Charleen Yu Chih ^a   Hanna, Gabi ^a   Rich, Jeremy N ^e   Provenzale, James M ^a   Dewhirst, Mark W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d STANFORD UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIGALLOCATECHIN GALLATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; NITRIC OXIDE; STAT1 PROTEIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BIOLUMINESCENCE; CELL ACTIVITY; CELL DEATH; CELL REPORTER ACTIVITY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; MICE, NUDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RANDOM ALLOCATION; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84886018696     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1345     Document Type: Article

References (50)

1. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
2. Carmeliet P, Dor Y, Herbert J.M., Fukumura D., Brusselmans K, Dewerchin M, et al Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394:485-90.
3. Moeller BJ, Cao Y, Li C.Y., Dewhirst MW Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5:429-41.
4. Li Z, Bao S, Wu Q., Wang H, Eyler C, Sathornsumetee S., et al Hypoxiainducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15:501-13.
5. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8:705-13.
6. Generali D, Berruti A, Brizzi M.P., Campo L., Bonardi S, Wigfield S, et al Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006; 12:4562-8.
7. 2 sensing. Science 2001; 292:464-8.
8. 2-regulated prolyl hydroxylation. Science 2001; 292:468-72.
9. Li F, Sonveaux P, Rabbani Z.N., Liu S., Yan B, Huang Q, et al Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 2007; 26:63-74.
10. Jeong JW, Bae MK, Ahn M.Y., Kim SH, Sohn TK, Bae MH, et al Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002; 111:709-20.
11. Lando D, Peet DJ, Gorman J.J., Whelan DA, Whitelaw ML, Bruick RK FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002; 16: 1466-71.
12. Berchner-Pfannschmidt U., Tug S, Kirsch M., Fandrey J. Oxygensensing under the influence of nitric oxide. Cell Signal 2010; 22:349-56.
13. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8:425-37.
14. Cao Y, Li CY, Moeller B.J., Yu D., Zhao Y, Dreher MR, et al Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res 2005; 65:5498-505.
15. Lee K, Qian DZ, Rey S, Wei H., Liu JO, Semenza GL Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumorinduced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A 2009; 106:2353-8.
16. Song X, Liu X, Chi W., Liu Y, Wei L, Wang X., et al Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 2006; 58:776-84.
17. Nardinocchi L, Puca R, Sacchi A., D'Orazi G. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer 2009; 8:1.
18. Laginha KM, Verwoert S, Charrois G.J., Allen TM Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005; 11:6944-9.
19. Charrois GJ, Allen TM Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004; 1663:167-77.
20. Lee ES, Na K, Bae YH Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005; 103:405-18.
21. Cao Y, Sonveaux P, Liu S., Zhao Y, Mi J, Clary B.M., et al Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 2007; 67:3835-44.
22. Kimura H, Weisz A, Kurashima Y., Hashimoto K, Ogura T, D'Acquisto F, et al Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000; 95:189-97.
23. Metzen E, Zhou J, Jelkmann W., Fandrey J, Brune B. Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. Mol Biol Cell 2003; 14:3470-81.
24. Sandau KB, Fandrey J, Brune B. Accumulation of HIF-1alpha underthe influence of nitric oxide. Blood 2001; 97:1009-15.
25. Tsoyi K, Nizamutdinova IT, Jang H.J., Mun L., Kim HJ, Seo HG, et al Carbon monoxide from CORM-2 reduces HMGB1 release through regulation of IFN-beta/JAK2/STAT-1/INOS/NO signaling but not COX2 in TLR-activated macrophages. Shock 2010; 34:608-14.
26. Menegazzi M, Tedeschi E, Dussin D., De Prati AC, Cavalieri E, Mariotto S, et al Anti-interferon gamma action of epigallocatechin-3-gallate mediated by specific inhibition of STAT1 activation. FASEB J 2001; 15:1309-11.
27. Iwashina M, Shichiri M, Marumo F., Hirata Y. Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells. Circulation 1998; 98:1212-8.
28. Thomas M, Finnegan CE, Rogers K.M., Purcell JW, Trimble A, Johnston PG, et al STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res 2004; 64:8357-64.
29. Talks KL, Turley H, Gatter K.C., Maxwell PH, Pugh CW, Ratcliffe PJ, et al The expression and distribution of the hypoxia-inducible factors HIF1alpha and HIF-2alpha in normal human tissues, cancers, and tumorassociated macrophages. Am J Pathol 2000; 157:411-21.
30. Brown JM, Wilson WR Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4:437-47.
31. Mitra S, Cassar SE, Niles D.J., Puskas JA, Frelinger JG, Foster TH Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha. Mol Cancer Ther 2006; 5: 3268-74.
32. Moon EJ, Sonveaux P, Porporato P.E., Danhier P., Gallez B, Batinic Haberle I, et al NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment. Proc Natl Acad Sci U S A 2010; 107:20477-82.
33. Primeau AJ, Rendon A, Hedley D., Lilge L, Tannock IF The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005; 11:8782-8.
34. Berchner-Pfannschmidt U., Yamac H, Trinidad B., Fandrey J. Nitric oxide modulates oxygen sensing by hypoxia-inducible factor 1dependent induction of prolyl hydroxylase 2. J Biol Chem 2007; 282: 1788-96.
35. +/-)-S-nitroso-N-acetylpenicillamine, stabilizes transactive hypoxia-inducible factor-1alpha by inhibiting von Hippel-Lindau recruitment and asparagine hydroxylation. Mol Pharmacol 2008; 74: 236-45.
36. Gianni L, Zweier JL, Levy A, Myers CE Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen. J Biol Chem 1985; 260:6820-6.
37. Sinha BK, Katki AG, Batist G, Cowan K.H., Myers CE Adriamycinstimulated hydroxyl radical formation in human breast tumor cells. Biochem Pharmacol 1987; 36:793-6.
38. Fornari FA, Randolph JK, Yalowich J.C., Ritke MK, Gewirtz DA Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994; 45:649-56.
39. Giaccia A, Siim BG, Johnson RS HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2:803-11.
40. Lee TH, Seng S, Sekine M., Hinton C, Fu Y, Avraham H.K., et al Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007; 4:e186.
41. Guo P, Fang Q, Tao H.Q., Schafer CA, Fenton BM, Ding I, et al Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo. Cancer Res 2003; 63:4684-91.
42. Pidgeon GP, Barr MP, Harmey J.H., Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001; 85:273-8.
43. Moeller BJ, Dreher MR, Rabbani Z.N., Schroeder T., Cao Y, Li CY, et al Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005; 8:99-110.
44. Yamaguchi K, Saito H, Oro S., Tatebe S, Ikeguchi M, Tsujitani S. Expression of inducible nitric oxide synthase is significantly correlated with expression of vascular endothelial growth factor and dendritic cell infiltration in patients with advanced gastric carcinoma. Oncology 2005; 68:471-8.
45. Wang H, Mohammad RM, Werdell J, Shekhar PV p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: in vitro versus in vivo activity. Int J Mol Med 1998; 1:915-23.
46. Nagasawa H, Li CY, Maki C.G., Imrich AC, Little JB Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. Cancer Res 1995; 55:1842-6.
47. Fryknas M, Dhar S, Oberg F., Rickardson L, Rydaker M, Goransson H., et al STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. Int J Cancer 2007; 120: 189-95.
48. Muerkoster SS, Lust J, Arlt A., Hasler R, Witt M, Sebens T., et al Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene 2006; 25:3973-81.
49. Li L, Zhang J, Jin B., Block ER, Patel JM Nitric oxide upregulation of caspase-8 mRNA expression in lung endothelial cells: role of JAK2/ STAT-1 signaling. Mol Cell Biochem 2007; 305:71-7.
50. Zhang H, Wong CC, Wei H, Gilkes D.M., Korangath P., Chaturvedi P, et al HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the ungs. Oncogene 2012; 31:1757-70.